Impact of COVID-19 Pandemic on Initiation of Immunosuppressive Treatment in Immune-Mediated Inflammatory Diseases in Austria: A Nationwide Retrospective Study
Objective: Conventional immunosuppressive and advanced targeted therapies, including biological medications and small molecules, are a mainstay in the treatment of immune-mediated inflammatory diseases (IMID). However, the COVID-19 pandemic caused concerns over these drugs’ safety regarding the risk...
Main Authors: | Maximilian Kutschera, Valentin Ritschl, Berthold Reichardt, Tanja Stamm, Hans Kiener, Harald Maier, Walter Reinisch, Bernhard Benka, Gottfried Novacek |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-09-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2077-0383/11/18/5308 |
Similar Items
-
Systemic Inflammatory Disorders, Immunosuppressive Treatment and Increase Risk of Head and Neck Cancers—A Narrative Review of Potential Physiopathological and Biological Mechanisms
by: Nuno Vale, et al.
Published: (2023-09-01) -
Tyk2 Targeting in Immune-Mediated Inflammatory Diseases
by: Lluís Rusiñol, et al.
Published: (2023-02-01) -
Could Periodontitis Aggravate Psoriasis?—An Update by Systematic Review
by: Juan José Meneu, et al.
Published: (2023-01-01) -
Vedolizumab in the treatment of inflammatory bowel diseases: whom and how?
by: A. O. Golovenko, et al.
Published: (2018-10-01) -
Therapeutic dilemmas in the management of a patient with long-term rheumatoid arthritis and severe clinical presentation of SARS-CoV-2 infection
by: Janković Tanja, et al.
Published: (2023-01-01)